Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

POINT Biopharma

3 clinical trials

1 abstract

Clinical trial
A Phase 3, Open-Label, Randomized Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)
Status: Active (not recruiting), Estimated PCD: 2023-11-01
Clinical trial
[Ac-225]-PSMA-62 Phase I/II Clinical Trial to Characterize Efficacy, Safety, Tolerability, and Dosimetry in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer (ACCEL)
Status: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Abstract
FRONTIER: FAPi radioligand open-label, phase 1 study to evaluate safety, tolerability and dosimetry of [Lu-177]-PNT6555—A dose escalation study for treatment of patients with select solid tumors.
Org: Memorial Sloan Kettering Cancer Center, Jewish General Hospital Stroll Cancer Prevention Centre, Centre Hospitalier de l’Universite de Montreal, University of Pennsylvania Perelman School of Medicine, Princess Margaret Hospital,